Medicine composition for treating progressive nerve degeneration disease

A pharmaceutical composition and neurodegeneration technology, applied in the direction of drug combination, pharmaceutical formula, neurological diseases, etc., can solve the problem of high risk of neurons

Inactive Publication Date: 2008-10-22
ACAD SINIC
View PDF7 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, even though clinical-grade hESC lines are readily available, transplanting neurons derived from in vitro differentiated HESCs is risky and requires highly invasive intracerebral injections to deliver neurons into the patient's brain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating progressive nerve degeneration disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Granulocyte colony-stimulating factor ameliorates learning deficit in a mouse model of Alzheimer's disease

[0035] Alzheimer's-like progressive neurodegeneration was induced in mice by intraventricular injection of aggregated Aβ-type peptides (as previously described by Yan et al.)

[0036] Aggregated Aβ-type peptides were prepared from 10 mM soluble Aβ (1-42) Prepare in solution in 0.01 M phosphate buffer, pH 7.4. Aβ-type peptides were purchased from Sigma-Aldrich (St. Louis, MO). Aβ solutions were heated at 37°C for three days to form aggregated Aβ-type peptides and stored at -70°C before use. Eight-week-old C57BL / 6 male mice were anesthetized with intraperitoneal sodium pentobarbital (40 mg / kg) before injection of aggregated Aβ-type peptides. The aggregated A[beta]-type peptides were then injected stereotaxically into the dorsal hippocampus and both sides of the cerebral cortex using a 26-gauge needle attached to a Hamilton microregulation syringe (Ha...

Embodiment 2

[0044] Long-lasting effects of granulocyte colony-stimulating factor

[0045] In order to test whether granulocyte colony-stimulating factor (G-CSF) can have a long-term therapeutic effect, the cognitive ability of Tg2576 mice was analyzed 3 months after treatment. To this end, 10 12-month-old mice were divided into two groups and tested with a water maze task as described above before and 3 months after subcutaneous injection of PBS and granulocyte colony-stimulating factor (G-CSF), respectively. like figure 1 As shown, the average latency of Tg2576 mice treated with PBS (3 months after Tg2576 injected with PBS) and not treated with PBS (Tg2576 administered with PBS injected control) was generally high. Clearly, however, granulocyte colony-stimulating factor-treated mice had significantly better learning / memory abilities, even 3 months after treatment (Tg2576 injected with G-CSF 3 months later vs Tg2576 administered with G-CSF injection control comparison). These data demo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a drug combination for treating progressive nerve degradation or inhabiting the happening of the progressive nerve degradation of a high risk curer. The drug combination at least comprises the agent of a granulocyte colony stimulating factor receptor in effective quantity, thereby moving hematopoietic stem cells to peripheral blood from bone marrow. The combination can also be used for inhibiting the happening of the progressive nerve degradation on the high risk curer. In addition, a choice of the methods is provided for treating the agent of the granulocyte colony stimulating factor receptor of the progressive nerve degradation.

Description

technical field [0001] The present invention relates to a pharmaceutical composition of a granulocyte colony-stimulating factor receptor agent and its use in the manufacture of medicines. Background technique [0002] Progressive neurodegenerative disorders (PNDs), such as Alzheimer's disease, cause slow but invariable neuronal loss accompanied by a reduction in cognitive or motor function, with the result being the death of the subject. Progressive neurodegeneration has a devastating impact on the quality of life of those affected and their families. In addition, progressive neurodegeneration imposes a heavy health care burden on society. In fact, such diseases mainly affect the expanding elderly population, so their prevalence and social impact are expected to increase in the coming years. [0003] One of the most promising treatments for progressive neurodegeneration is neuron replacement with transplanted neurons derived from stem cells, which in very small numbers are...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P25/28
Inventor 沈哲鲲蔡坤哲
Owner ACAD SINIC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap